Government to spend 3.8 bn over R&D of Ilyang’s leukemia medicine

Published: 2008-11-26 06:26:00

Updated: 2008-11-26 06:26:00

The government plans to earmark 3.8 billion won for Ilyang Pharm’s new leukemia treatment candidate IY5511 that has the potential to be used as a drug, it was announced on November 24.

The Korea Health Industry Development Institute said that IY5511 has been selected as one of the state-funded...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK